Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

NCT02709083 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Original principal investigator left institution

Conditions

Chronic Myelogenous Leukemia
Chronic Myeloid Leukemia
Leukemia

Interventions

DRUG: Dasatinib
DRUG: Imatinib Mesylate
DRUG: Nilotinib

Sponsor

Emory University